A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

300

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

August 31, 2029

Study Completion Date

February 28, 2030

Conditions

Nephritis, LupusLupus Erythematosus, Systemic

Interventions

DRUG

Cenerimod

Cenerimod will be supplied as a film-coated tablets at the dose of 4 mg.

DRUG

Placebo

Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod.

All Listed Sponsors

lead

Viatris Innovation GmbH

INDUSTRY